Abstract C041: Safety and pharmacokinetic results from a phase 1, multicenter, open-label study of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with advanced HER2-positive breast cancer

Mapping Intimacies ◽

10.1158/1535-7163.targ-19-c041 ◽

2019 ◽

Author(s):

Dwan-Ying Chang ◽

Chia-Chi Lin ◽

Tom Wei-Wu Chen ◽

Ching-Hung Lin ◽

Jih-Hsiang Lee ◽

...

Keyword(s):

Breast Cancer ◽

Phase 1 ◽

Her2 Positive ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Her2 Positive Breast Cancer ◽

Positive Breast Cancer

Get full-text (via PubEx)

Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Local Advanced or Metastatic, HER2 Positive Breast Cancer.

Case Medical Research ◽

10.31525/ct1-nct03944499 ◽

2019 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Solid Tumors ◽

Phase 1 ◽

Advanced Solid Tumors ◽

Her2 Positive ◽

Phase 1 Study ◽

Her2 Positive Breast Cancer ◽

Local Advanced ◽

Positive Breast Cancer

Get full-text (via PubEx)

Faculty Opinions recommendation of 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718043513.793482079 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Randomised Controlled Trial ◽

Controlled Trial ◽

Her2 Positive ◽

Open Label ◽

Adjuvant Trastuzumab ◽

Her2 Positive Breast Cancer ◽

Randomised Controlled ◽

Positive Breast Cancer

Get full-text (via PubEx)

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(18)30570-9 ◽

2018 ◽

Vol 19 (12) ◽

pp. 1630-1640 ◽

Cited By ~ 34

Author(s):

Mette S van Ramshorst ◽

Anna van der Voort ◽

Erik D van Werkhoven ◽

Ingrid A Mandjes ◽

Inge Kemper ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Her2 Positive ◽

Open Label ◽

Phase 3 ◽

Her2 Positive Breast Cancer ◽

Positive Breast Cancer

Get full-text (via PubEx)

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)00373-3 ◽

2015 ◽

Vol 16 (16) ◽

pp. 1700-1710 ◽

Cited By ~ 65

Author(s):

Javier Cortés ◽

Véronique Dieras ◽

Jungsil Ro ◽

Jérôme Barriere ◽

Thomas Bachelot ◽

...

Keyword(s):

Breast Cancer ◽

Brain Metastases ◽

Phase 2 ◽

Her2 Positive ◽

Open Label ◽

Multicentre Phase ◽

Her2 Positive Breast Cancer ◽

Phase 2 Trial ◽

Choice Of Treatment ◽

Positive Breast Cancer

Get full-text (via PubEx)

Abstract OT1-03-03: Phase II, open label, randomized, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with operable or locally advanced/Inflammatory HER2-positive breast cancer. ImmunHER trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)

10.1158/1538-7445.sabcs17-ot1-03-03 ◽

2018 ◽

Author(s):

A Musolino ◽

S Gori ◽

L Cavanna ◽

C Graiff ◽

A Frassoldati ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Mechanism Of Action ◽

Locally Advanced ◽

Her2 Positive ◽

Open Label ◽

Her2 Positive Breast Cancer ◽

Immune Mediated ◽

Positive Breast Cancer

Get full-text (via PubEx)

Abstract P4-14-08: Apatinib combined with docetaxel and platinum as neoadjuvant treatment for triple-negative/HER2-positive breast cancer: A randomized, open-label, multicenter, phase 2 trial

10.1158/1538-7445.sabcs19-p4-14-08 ◽

2020 ◽

Author(s):

Yunjiang Liu ◽

Shuo Zhang

Keyword(s):

Breast Cancer ◽

Triple Negative ◽

Neoadjuvant Treatment ◽

Phase 2 ◽

Her2 Positive ◽

Open Label ◽

Her2 Positive Breast Cancer ◽

Phase 2 Trial ◽

Multicenter Phase ◽

Positive Breast Cancer

Get full-text (via PubEx)

AVATAXHER: An open-label, randomized, multicenter study investigating the addition of bevacizumab (B) to neoadjuvant trastuzumab (T) plus docetaxel (D) in patients with early stage HER2-positive breast cancer (HER2+ BC) stratified according to PET change after one therapy cycle.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.507 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 507-507 ◽

Cited By ~ 4

Author(s):

Bruno P. Coudert ◽

Jean-Yves Pierga ◽

Marie-Ange Mouret-Reynier ◽

Khaldoun Kerrou ◽

Jean-Marc Ferrero ◽

...

Keyword(s):

Breast Cancer ◽

Multicenter Study ◽

Early Stage ◽

Her2 Positive ◽

Open Label ◽

Her2 Positive Breast Cancer ◽

Positive Breast Cancer

Get full-text (via PubEx)

Faculty Opinions recommendation of Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.735680777.793565214 ◽

2019 ◽

Author(s):

Scott Kaufmann

Keyword(s):

Breast Cancer ◽

Phase 1 ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Phase 1 Study ◽

Expansion Phase ◽

Her2 Positive Breast Cancer ◽

Previously Treated ◽

Positive Breast Cancer

Get full-text (via PubEx)

Abstract PS13-12: Apatinib combined with taxanes and platinum neoadjuvant chemotherapy for patients with triple-negative and HER2-positive breast cancer: A multicenter, randomized, open-label, phase II trial

10.1158/1538-7445.sabcs20-ps13-12 ◽

2021 ◽

Author(s):

Yunjiang Liu ◽

Xiangmei Zhang ◽

Li Wang ◽

Miao Cao ◽

Shuo Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Trial ◽

Her2 Positive ◽

Open Label ◽

Her2 Positive Breast Cancer ◽

Open Label Phase ◽

Positive Breast Cancer

Get full-text (via PubEx)

Abstract P1-18-16: A phase 1 study of ARX788, a HER2-targeting antibody-drug conjugate, in patients with metastatic HER2-positive breast cancer

10.1158/1538-7445.sabcs19-p1-18-16 ◽

2020 ◽

Cited By ~ 1

Author(s):

Xichun Hu ◽

Jian Zhang ◽

Dongmei Ji ◽

Gang Xia ◽

Yanping Ji ◽

...

Keyword(s):

Breast Cancer ◽

Phase 1 ◽

Antibody Drug Conjugate ◽

Her2 Positive ◽

Phase 1 Study ◽

Drug Conjugate ◽

Her2 Positive Breast Cancer ◽

Antibody Drug ◽

Positive Breast Cancer

Get full-text (via PubEx)